OncoMatch/Clinical Trials/NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Is NCT06646276 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including BMS-986489 (BMS-986012+Nivolumab) and Atezolizumab for extensive-stage small cell lung cancer.
Treatment: BMS-986489 (BMS-986012+Nivolumab) · Atezolizumab · Carboplatin · Etoposide — The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Prior therapy
Cannot have received: any treatment for extensive stage small cell lung cancer
already received certain types of treatment for extensive stage small cell lung cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center, PC · Daphne, Alabama
- Local Institution - 0283 · Hot Springs, Arkansas
- Florida Cancer Specialists - South · Fort Myers, Florida
- Mid Florida Hematology and Oncology Center · Orange City, Florida
- Florida Cancer Specialists - North · St. Petersburg, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify